[ad_1]
Adopted FDA Today, a drug for the treatment of severe forms of asthma has significantly improved the health of people with rare chronic immune disorders. (HES) Where other treatments were ineffective.
The discovery comes from a small clinical trial conducted by scientists from the National Institute of Allergic and Infectious Diseases(NIAID) , Part of the National Institutes of Health.
"Antony Fushi", director of the institute "People with rare immunodeficiency disease often have few effective treatment options, if any. "
The researchers noted that immune disorders "HES" This is due to a higher than normal number of white blood cells called "peritoneal" in the blood, tissues or both.
While most people have 0 to 500% "peritoneal" per microliter of blood, people with HES They usually have more than 1500 eosinophils / ul.
Symptoms vary "HES" Is widely spread from one patient to another and can affect the heart, lungs, skin, digestive system, central nervous system and other body organs.
The drug that has been tested at this stage of clinical trials is "Benralizumab", Which consists of an antibiotic linked to a protein, called IL-5 Receiversα On the surface of eosinophils, scientists assume that once this association is established, immune cells called natural killer cells come closer and destroy eosinophils..
Read the source of the seventh day
[ad_2]
Source link
